Kimberly A Lane

US Patent:

8557808, Oct 15, 2013

Filed:

Dec 9, 2010

Appl. No.:

13/514418

Inventors:

Matthew R. Redinbo - Durham NC, US
Sridhar Mani - Riverdale NY, US
Alfred Williams - Durham NC, US
John Scott - Durham NC, US
Li-An Yeh - Cary NC, US
Bret David Wallace - Chapel Hill NC, US
Kimberly Terry Lane - Christiansburg VA, US

Assignee:

North Carolina Central University - Durham NC
The University of North Carolina at Chapel Hill - Chapel Hill NC
Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

A61K 31/5377
A61K 31/496
A61K 31/381
A61K 31/47
C07D 413/14
C07D 239/00
C07D 491/056
C07D 333/04
C07D 215/00

US Classification:

5142328, 51425216, 51425411, 514312, 514447, 544112, 544249, 544278, 544377, 546157, 549 68

Abstract:

Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds.